Session (CTI)

Issue China’s biopharmaceutical ecosystem has undergone a profound transformation over the past decade, emerging as a significant contributor to global drug discovery, clinical development, and real-world evidence generation. Increasing licensing agreements between multinational companies and Chinese innovators, alongside the growing participation of Chinese sites in multinational studies, have expanded the visibility of data originating from China in regulatory, reimbursement, and access discussions beyond its borders. This evolution raises important questions for HTA bodies, payers, and industry decision-makers. Under what circumstances can evidence generated in one healthcare setting inform decisions in another? How should stakeholders assess the relevance of clinical and real-world data derived from Chinese populations when evaluating effectiveness, value, and uncertainty? As healthcare systems face mounting pressure to accelerate patient access while maintaining rigorous evidence standards, these questions are becoming increasingly consequential. Overview This issue panel will examine the growing influence of evidence generated in China on global health technology assessment, reimbursement, and access decisions. Drawing on perspectives from industry, academia, and HTA stakeholders, the discussion will explore how evolving research capabilities, regulatory reforms, and expanding data infrastructure are shaping evidence packages used to support market access across regions. Panelists will discuss opportunities to leverage data generated in China to address evidence gaps, improve development efficiency, and support decision-making throughout the product lifecycle. Equally, the session will consider ongoing challenges related to transferability, methodological expectations, population heterogeneity, and jurisdiction-specific evidence requirements. Through a balanced and forward-looking discussion, the panel will explore whether the emergence of China as a major evidence-generation hub is reshaping global approaches to assessing value, managing uncertainty, and enabling timely patient access to innovation.